Mylan (NSDQ:MYL) revealed in its annual report yesterday that EpiPen sales in the U.S. were down $655.4 million last year compared to 2016.
The company, which faces continued backlash over the price of its emergency allergy treatment, cited the launch of a generic version of its device, higher governmental rebates and increased competition as reasons for EpiPen’s declining sales in North America.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan: Generic competition pushes EpiPen sales down appeared first on MassDevice.